

XIVth International Workshop of the German CLL Study Group

April 18th – 20th 2024

Balloni Cologne (Germany)

Scientific Lead

Michael Hallek, Cologne

Program Committee

Othman Al-Sawaf, Cologne

Barbara Eichhorst, Cologne

Kirsten Fischer, Cologne

Michael Hallek, Cologne

Young Investigator Meeting 2024

Petra Langerbeins, Cologne

Deborah Stephens, Chapel Hill

Loïc Ysebaert, Toulouse



The European Board for Accreditation in Hematology (EBAH) has certified this event with 8.5 points and the Ärztekammer Nordrhein with 10 (7 plus 3) points.



Thursday, April 18th 2024

Brauerei zur Malzmühle

Heumarkt 6 | 50667 Köln

06.00 – 07.30 p.m. Strategy commission (closed session)

07.00 – 10.00 p.m. Welcome reception

07.45 – 08.15 p.m. **Opening Keynote Lecture** A P Kater
Immune function in patients with CLL

08.15 – 10.00 p.m. Working Dinner

Friday, April 19th 2024

BALLONI Hallen

Ehrenfeldgürtel 96 | 50823 Köln

08.00 – 09.00 a.m. CLL-RT2 Investigator Meeting (closed session)

09.00 – 09.20 a.m. Check-In

09.20 – 09.30 a.m. Welcome M Hallek

Young Investigators' Meeting (YIM)

09.30 – 11.00 a.m. YIM Session I: Clinical & Translational Research *Chairs: P Langerbeins, L Ysebaert*

09.30 – 09.45 a.m. Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia I Romano

09.45 – 10.00 a.m. Incidence of Richter transformation in patients with chronic lymphocytic leukemia (CLL): a cohort study evaluating different therapeutic eras P J Hampel

10.00 – 10.15 a.m. Prevalence and clinical impact of clonal hematopoiesis in chronic lymphocytic leukemia R Moia

10.15 – 10.30 a.m. Preclinical efficacy of the BCL2i venetoclax combined with MEKi cobimetinib or SYKi entospletinib in BTKi-refractory CLL patients harboring BTK mutations S Martindale

10.30 – 10.45 a.m. Targeting NF- κ B-inducing kinase (NIK) in chronic lymphocytic leukaemia I Ashworth

10.45 – 11.00 a.m. The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed by Shallow Depth RNA Sequencing T H L Do

| | | |
|--|--|-------------------------------------|
| 11.00 – 11.30 a.m. Coffee & Tea | | |
| 11.30 – 01.00 p.m. | YIM Session II: Translational & Basic Research | <i>Chairs: D Stephens, M Hallek</i> |
| 11.30 – 11.45 a.m. | TLR9 signaling is a potential tumor escape mechanism following B-cell receptor targeted treatments in subsets of | E Kennedy |
| 11.45 – 12.00 a.m. | BH3 Profiling Identifies Anti-Apoptotic Dependencies and Therapeutic Vulnerabilities in Primary Richter Transformation (RT) Cells and in a Genetically-Engineered Murine Model of RT | N Javidi-Sharifi |
| 12.00 – 12.15 p.m. | LYN kinase activity and its regulator CSK are key players in CLL supporting macrophages | V Kohlhas |
| 12.15 – 12.30 p.m. | Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition | K Mashima |
| 12.30 – 12.45 p.m. | Role of G protein-coupled receptor kinase 2 (GRK2) in the localization and activation of leukemic cells | C Cassarino |
| 12.45 – 13.00 p.m. | Rps15-S138F mutation results in translational errors underlying onset of chronic lymphocytic leukemia | N Ruthen |
| 01.00 – 01.45 p.m. Lunch | | |
| 01.45 – 03.20 p.m. | German CLL Study Group studies | <i>Chairs: P Staber, K Fischer</i> |
| | Phase II/III trials completed | |
| 01.45 – 01.55 p.m. | CLL13 – Minimal Residual Disease: status and outcome | M Ritgen |
| 01.55 – 02.05 p.m. | CLL12 CLL13 CLL14 – Genetic subgroups: different studies, same findings? | E Tausch |
| | Ongoing trials | |
| 02.05 – 02.10 p.m. | CLL ReVenG | M Davids |
| 02.10 – 02.15 p.m. | CLL16 | N Kutsch |
| 02.15 – 02.20 p.m. | CLL17 | O Al-Sawaf |
| 02.20 – 02.30 p.m. | Discussion | Plenum |
| | Ongoing trials with results | |
| 02.30 – 02.35 p.m. | CLLRT1 | B Eichhorst |
| 02.35 – 02.40 p.m. | CLLFrail | F Simon |

| | | |
|---------------------------|---|--|
| 02.40 – 02.50 p.m. | Discussion | Plenum |
| | Planned trials | |
| 02.50 – 02.55 p.m. | CLL18 | P Cramer |
| 02.55 – 03.00 p.m. | CLLRT2 | S Stilgenbauer |
| 03.00 – 03.05 p.m. | Shall we address the tumor microenvironment? | A vom Stein |
| 03.05 – 03.10 p.m. | Bendamustine debulking – yes or no? | J v Tresckow |
| 03.10 – 03.20 p.m. | Discussion | Plenum |
| 03.20 – 03.50 pm | Coffee & Tea | |
| 03.50 – 04.50 p.m. | Session I: Genomics and biology of CLL | <i>Chairs: R Guizèze, C Herling</i> |
| 03.50 – 04.05 p.m. | Genomic Map of CLL | BA Knisbacher |
| 04.05 – 04.20 p.m. | Richter Transformation | F Nadeu |
| 04.20 – 04.35 p.m. | <i>TP53</i> and beyond | P Robbe |
| 04.35 – 04.50 p.m. | Genetic and epigenetic evolution | R Rosenquist |
| 04.50 – 05.50 p.m. | YIM Session III: Guided Poster Walk with Coffee & Tea | <i>Chairs: D Stephens, L Ysebaert, P Langerbeins</i> |
| 04.50 – 05.00 p.m. | Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway | L Terzi di Bergamo |
| 05.00 – 05.10 p.m. | Combined therapy of endocytosis inhibitors and a novel glycoengineered anti-ROR1 antibody to enhance antibody-dependent cellular cytotoxicity (ADCC) against chronic lymphocytic leukemia | K Hasan |
| 05.10 – 05.20 p.m. | A Comparative Study of Different Macrophage Feeder Systems for the Support of Chronic Lymphocytic Leukemia Survival | H Jestrabek |
| 05.20 – 05.30 p.m. | CAR T cells generated from CLL patients are characterized by determinants of immune dysfunction that may be positively modulated by treatment with targeted agents | F Perutelli |
| 05.30 – 05.40 p.m. | Venetoclax resistant cells are sensitive to anti-CD20 monoclonal antibodies. | V J Sarapura Martinez |
| 05.40 – 05.50 p.m. | Utility of the international chronic lymphocytic leukemia prognostic index in front-line treatment with targeted drugs | S Robrecht |

| | | |
|---------------------------|--|---------------------------------------|
| 05.50 – 06.20 p.m. | AbbVie Satellite Symposium Time limited treatment regimens in CLL – Present or Future? | S Stilgenbauer |
| 06.20 – 06.50 p.m. | AstraZeneca Satellite Symposium Pattern of Resistance in CLL and its Clinical Implications | <i>Chair: C Herling</i> O Al-Sawaf |
| 06.50 – 07.40 p.m. | Flying Dinner | |
| 07.40 – 07.50 p.m. | Introduction | M Hallek |
| 07.50 – 08.20 p.m. | Keynote Lecture | J Woyach |
| 08.20 – 10.00 p.m. | Get together | |

Saturday, April 20th 2024

BALLONI Hallen

Ehrenfeldgürtel 96 | 50823 Köln

| | | |
|---------------------------|--|--|
| 08.00 – 09.00 a.m. | CLL18 Kick-Off Meeting (closed session) | |
| 09.00 – 09.15 a.m. | Welcome | M Hallek |
| 09.15 – 10.00 a.m. | Session II: Treatment of CLL | <i>Chairs: M Davids, L Scarfò</i> |
| 09.15 – 09.30 a.m. | Selecting a first-line treatment – what do we know, what do we need, what is standard? | T Munir |
| 09.30 – 09.45 a.m. | Relapsed CLL – is it just second first-line? | P Thompson |
| 09.45 – 10.00 a.m. | Double Refractory (BTKi and BCL2i) – what comes next? | M Hallek |
| 10.00 – 10.30 a.m. | BeiGene Satellite Symposium Mental health in patients with CLL | L Fallowfield C M Wendtner |
| 10.30 – 11.00 a.m. | Coffee & Tea | |
| 11.00 – 11.30 a.m. | Janssen Satellite Symposium CLL therapy today and tomorrow | <i>Chair: M Trepel</i> P Ghia |
| 11.30 – 12.15 p.m. | Session III: Daily challenges in CLL management | <i>Chairs: P Thornton, T Kipps</i> |
| 11.30 – 11.45 a.m. | Autoimmune conditions | M Coscia |
| 11.45 – 12.00 p.m. | Infections | L Scarfò |
| 12.00 – 12.15 p.m. | Richter Transformation | R Guièze |

12.15 – 12.30 p.m. **YIM Award**

*Chairs: D Stephens,
L Ysebaert, P Langerbeins*

12.30 – 01.30 p.m. **Lunch**

01.30 – 02.00 p.m. **Lilly Satellite Symposium**

J v Tresckow

Latest CLL data – ready for clinical routine?

H Huber

02.00 – 03.00 p.m. **Session IV: Perspectives**

Chairs: D Rossi, J Brown

02.00 – 02.15 p.m. Novel targets

A Danilov

02.15 – 02.30 p.m. Cellular and bispecific therapies

F Bosch

02.30 – 02.45 p.m. Prognostic & predictive factors

I Ahn

02.45 – 03.00 p.m. Dream your study

S Parikh

03.00 – 03.15 p.m. **Closing remarks**

M Hallek

We would like to thank **AbbVie Deutschland GmbH & Co. KG**, **AstraZeneca GmbH**, **BeiGene Germany GmbH**, **Janssen-Cilag GmbH** and **Lilly Deutschland GmbH** for their kind support of this meeting with Sponsorship Package A (Platin Sponsors | €70,000 each) and **Roche Pharma AG** with Sponsorship Package B (Gold Sponsor | €40,000). **Bristol-Myers Squibb GmbH & Co. KGaA** and **Prelude Therapeutics, Inc.** are supporting the conference with Sponsorship Package D (Bronze Sponsors | €10.000 each), **MSD Sharp & Dohme GmbH** is contributing €5,000 (Copper Sponsor) to the International GCLLSG workshop. The sponsors' contributions will be used for event management, website, venue, catering and working lunches, hotel accommodation, travel expenses (of speakers, moderators, strategy committee members), video reports, certification, insurance, printing materials and technical equipment. The organizers, the scientific lead and the speakers confirm that the event is product-neutral. Any conflicts of interest of the speakers will be disclosed prior to the presentation.

abbvie

AstraZeneca 

 BeiGene

 Bristol Myers Squibb™

janssen 
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

Lilly

 MSD

 Prelude
THERAPEUTICS

 Roche

On behalf of the German CLL Study Group (GCLLSG) and the Kompetenznetz Maligne Lymphome e.V. (KML) this event is organized by:

KARO

KARO - KML Academic Research Organisation GmbH

Gleueler Str. 176-178 | D-50935 Köln | info@k-aro.de | https://k-aro.de